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DYNC2LI1 mutations broaden 
the clinical spectrum of dynein-2 
defects
Kristin Kessler1, Ina Wunderlich1, Steffen Uebe1, Nathalie S Falk2, Andreas Gießl2, 
Johann Helmut Brandstätter2, Bernt Popp1, Patricia Klinger3, Arif B Ekici1, Heinrich Sticht4, 
Helmuth-Günther Dörr5, André Reis1, Ronald Roepman6, Eva Seemanová7 & 
Christian T Thiel1
Skeletal ciliopathies are a heterogeneous group of autosomal recessive osteochondrodysplasias 
caused by defects in formation, maintenance and function of the primary cilium. Mutations in 
the underlying genes affect the molecular motors, intraflagellar transport complexes (IFT), or the 
basal body. The more severe phenotypes are caused by defects of genes of the dynein-2 complex, 
where mutations in DYNC2H1, WDR34 and WDR60 have been identified. In a patient with a Jeune-
like phenotype we performed exome sequencing and identified compound heterozygous missense 
and nonsense mutations in DYNC2LI1 segregating with the phenotype. DYNC2LI1 is ubiquitously 
expressed and interacts with DYNC2H1 to form the dynein-2 complex important for retrograde IFT. 
Using DYNC2LI1 siRNA knockdown in fibroblasts we identified a significantly reduced cilia length 
proposed to affect cilia function. In addition, depletion of DYNC2LI1 induced altered cilia morphology 
with broadened ciliary tips and accumulation of IFT-B complex proteins in accordance with retrograde 
IFT defects. Our results expand the clinical spectrum of ciliopathies caused by defects of the dynein-2 
complex.
The primary cilium is a nearly ubiquitous organelle of non-proliferative vertebrate cells. This organelle 
functions as an antenna to sense extracellular stimuli via various ciliary membrane receptors and trans-
mits these signals into the cell to initiate intracellular transduction cascades of different signaling path-
ways1–4. These include the Hedgehog, Wnt, planar cell polarity, FGF, Notch, mTor, PDGF and the Hippo 
signaling pathways5–13.
Cilia play important roles in differentiation, migration, proliferation, determination of left-right 
asymmetry and are thus important for the embryonic and postnatal development and proper organ 
function in adulthood1,14,15. The non-motile primary cilium consists of two main components, the basal 
body complex on the cytoplasmic side of the cell membrane, and the ciliary axoneme, surrounded by 
a cytoplasmic membrane extending into the extracellular space. The axoneme is radially arranged by 
nine microtubule doublets growing out of the distal end of the basal body (9 × 2 + 0 structure). The 
basal body complex consists of a mother and daughter centriole embedded in the pericentriolar mate-
rial (PCM)3,4,14,16,17. The junction between the basal body and the axoneme, the transition zone, is a 
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specialized structure with a barrier function (“ciliary gate”), regulating the passage of ciliary proteins 
into or out of the primary cilium18,19.
During the cell cycle cells present a primary cilium in G0/G1 phase and before entering mitosis 
the cilium is disassembled. For assembly, maintenance and dismantling different proteins are required, 
brought to their destination via the intraflagellar transport (IFT). The IFT is a bidirectional transit system 
that transports cargos to the tip of the cilium (anterograde transport) and back to the base (retrograde 
transport)17,20,21. Kinesin-2 motors and subunits of the IFT-B complex are integral parts of the antero-
grade movement, whereas cytoplasmic dynein-2 and IFT-A components are responsible for retrograde 
transport16,22,23. Cell cycle regulatory signals, cytoplasmic vesicle transport systems and recruitment of 
all required IFT components at the right time and the right place are important for proper ciliogenesis.
Defects of genes encoding a variety of proteins involved in cilia formation, maintenance and func-
tion, such as IFT subcomponents and components of the ciliary axoneme, transition zone or basal body, 
lead to the broad phenotypic spectrum of ciliopathies15,24. Many of the associated phenotypes include 
brain malformations, polydactyly, kidney cysts, retinal degeneration, and skeletal abnormalities. Today, 
mutations in 14 different genes have been identified to be causative for skeletal ciliopathies. Because 
of the genetic heterogeneity of skeletal dysplasias, disrupted proteins affect either the dynein motor 
(DYNC2H1), or the core components of the IFT transport complexes (IFT43, IFT80, IFT122, IFT140, 
IFT172, WDR19, WDR34, WDR35, WDR60 and TTC21B) or the basal body region (NEK1, EVC, 
EVC2)25–30. The phenotypic spectrum of skeletal ciliopathies includes short ribs, narrow thorax, short 
stature, postaxial polydactyly and other skeletal abnormalities. These phenotypes are shared by the skel-
etal short-rib thoracic dysplasias (SRTD 1 - 12 [MIM 208500, 611263, 613091, 613819, 614376, 263520, 
614091, 615503, 266920, 615630, 615633, 269860]), Ellis-van Crefeld syndrome (EVC [MIM 225500]), 
cranioectodermal dysplasias (CED1-4 [MIM 218330, 613610, 614099, 614378]) and Weyers acrofacial 
dysostosis (WAD [MIM 193530])25,31–33.
Here, we performed exome sequencing in a family with a Jeune-like intermediate phenotype (SRTD 
and EVC overlapping clinical findings) and identified compound heterozygous nonsense and missense 
mutations in the DYNC2LI1 gene. DYNC2LI1 is known as a component of the dynein-2 complex impor-
tant for retrograde IFT34,35. Knockdown experiments resulted in shorter cilia with abnormally bulged 
tips, similar to other ciliopathies with retrograde IFT defects. Mutations in the light intermediate chain 
of the dynein-2 complex are further expanding the clinical spectrum of skeletal ciliopathies.
Results
Clinical features of patients with DYNC2LI1 mutations. The affected children were the offsprings 
of non-consanguineous parents (Supplementary Fig. 1a). The first child (patient 1) developed a respira-
tory distress syndrome and died at the age of 3 days. Three further pregnancies ended as missed abor-
tions. The second child (patient 2) developed well, but showed dysmorphic features. During the following 
pregnancy fetal postaxial polydactyly was noticed and the pregnancy terminated at 19th week of gestation 
(patient 3). The observed clinical features were classified between Ellis-van-Crefeld syndrome and Jeune 
syndrome. Although the affected children present with variable features they do share characteristics in 
common.
Patient 1 showed a polyhydramnion during pregnancy and was born at 38th weeks of gestation with 
a weight of 3300 g (0.3 s.d.) and a body length of 50 cm (–0.17 s.d.). Clinical findings included agenesis 
of the epiglottis, postaxial hexadactyly of the both hands and the right foot, hypoplastic nails, atrioven-
tricular septal defect and hepatosplenomegaly (Supplementary Fig. 1b-d). She presented with distinctive 
facial features characterized by medial cleft lip, low set ears, asymmetric tongue, hyperplastic gingivae, 
epicanthal fold and down-slanting palpebral fissures. A hypoplastic thorax led to a respiratory distress 
syndrome and the patient died two days after birth. Her karyotype was normal (46,XX).
Patient 2 also showed a polyhydramnion during pregnancy and was born at 40th week of gestation 
with a weight of 4120 g (1.53 s.d.) and a body length of 53 cm (0.59 s.d.). Her psychomotor development 
was normal. She spoke first words at 8 month and was able to walk independently at 14 month. She 
likewise presented with postaxial hexadactyly of the left hand, brachydactyly, a small medial cleft lip, a 
hypoplastic epiglottis and narrow thorax, in addition we observed a syndactyly VI/VII of the right hand 
(Supplementary Fig. 1e-g). Her facial feature include a broad and prominent forehead, a depressed nasal 
bridge, broad and up-slanting nasal tip and low set ears. She also went through respiratory distress syn-
drome but recovered after 2 month. Beside an episode of pneumonia she showed no signs of increases 
susceptibility to infections. No further malformation are known.
Patient 3 was the fetus after termination of the pregnancy at 19th week of gestation. During pregnancy 
polyhydramnion and postaxial hexadacytly was noticed (Supplementary Fig. 1h-j). In addition, the fetus 
presented with a medial cleft lip and a pronounced narrow thorax.
Radiological investigation of both girls were performed and revealed cone-shaped epiphysis of the 
phalangeal bones, a metaphyseal dysplasia and a narrow thorax with short ribs (personal communication 
with Prof. F. Majewksi), so an atypical Jeune syndrome was proposed (Supplementary Fig. 1k,l).
Whole exome sequencing and candidate screening. Exome sequencing has been demonstrated 
to be highly successful to identify the underlying genetic cause of autosomal recessive inherited enti-
ties36–41. After Agilent sure select capturing and exome sequencing of patient 2 we received 156.9 M 
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single end reads. 85.01% of the reads were mapped to the human genome version hg19 and 88.06% were 
on-target. 81.5% of the captured target was covered at least 5x with an average depth of 73.3-fold. A total 
of 52,679 variants were called, of which 2,076 were indels and 50,603 were single nucleotide variants. 
Based on the supposed rare incidence of the phenotype we excluded all frequent variants (above 0.01%), 
detected in any of the 666 in-house control individuals as well as all annotated variants of dbSNP132, 
the 1000genomes project (phase1), and the exome variant server (http://evs.gs.washington.edu/EVS). 
Excluding intergenic, intronic and synonymous variants and proposing an autosomal recessive inher-
itance led to 58 remaining, variants of unknown significance (VUS) in 4 genes. Based on the mutational 
effect of these variants, their conservation (PhyloP, GERP+ + ) and prediction program scores of SIFT, 
PolyPhen2 and MutationTaster, CADD only the two DYNC2LI1 mutations remained as candidate vari-
ants (Supplementary Table 1): A nonsense mutation c.622C > T (p.Arg208Ter; NM_001193464) in exon 
8 and the missense mutation c.662C > T (p.Thr221Ile; NM_001193464) in exon 9 of the DYNC2LI1 
gene. Nucleotide numbering uses + 1 as the A of the ATG translation initiation codon in the reference 
sequence, with the initiation codon as codon 1. Both variants could be confirmed by Sanger sequencing 
(Supplementary Fig. 2) and were not present in 858 control chromosomes of healthy individuals and in 
the 61,486 exomes of the Exome Aggregation Consortium (Exome Aggregation Consortium (ExAC), 
Cambridge, MA (URL: http://exac.broadinstitute.org) Nov. 2014). The affected positions are highly con-
served on nucleotide and amino acid level. No mutations in any of the known skeletal ciliopathy genes 
or other potential candidate genes were identified in this individual. The healthy mother, brother and son 
were carrier for the missense mutation p.Thr221Ile. DNA of the healthy father and the affected patients 
2 and 3 was not available. Based on the family history the nonsense mutation is paternally inherited. 
Therefore, the identified mutations are highly likely to be pathogenic.
DYNC2LI1 expression. We were not able to investigate the effect of the mutations on the expression 
level, as RNA of the patients was not available. We analyzed the expression levels of DYNC2LI1 in differ-
ent tissues with adult and fetal complementary DNA (cDNA) panels as well as in osteoblasts and chon-
drocytes. We examined a ubiquitous expression of DYNC2LI1 in all examined tissues (Supplementary 
Fig. 3). However, the overall highest expression levels were measured in chondrocytes, brain and kidney, 
no differences between fetal and adult tissues were observed except for a higher fetal expression in brain, 
kidney and lungs. This is in accordance with expression profiles of genes involved in structure and func-
tion of the primary cilium. In addition, we observed an expression of all 3 isoforms in the examined 
tissues with the highest contribution of the 2 longest isoforms.
Domain structure and structural effects of DYNC2LI1 mutations. To date, structural informa-
tion of DYNC2LI1 remains elusive, but comparison of the protein sequence (UniProt Q8TCX1-1) with 
known motifs predicted a P-loop containing nucleoside triphosphate hydrolases domain (position aa 30 
– 240) including a Dynein light intermediate chain domain (position aa 30 – 163; http://www.ebi.ac.uk/
interpro) (Fig. 1a). The most common functions of the P-loop containing nucleoside triphosphate hydro-
lases domains are the hydrolysis of nucleoside triphosphate42. Modelling of the nucleoside triphosphate 
hydrolase domain revealed that Thr221 (Fig. 1a,b) is close to the nucleoside binding site. An exchange 
from threonine to isoleucine in the mutant causes steric clashes and decreases the site of the nucleo-
side binding pocket (Fig.  1b). Therefore, the mutation is expected to impair the hydrolase function of 
DYNC2LI1.
As RNA was not available, we were not able to test whether the nonsense mutation might lead to 
mRNA decay or a shorter protein. However, a predicted truncated protein will miss the coiled-coil 
domain (position aa 315 – 340) which might be necessary for interaction with the coiled coil domain of 
DYNC2H1 of the dynein-2 complex.
DYNC2LI1 localizes to the primary cilium and DYNC2LI1 defects affect morphology and cilia 
length. As the dynein-2 complex is part of the retrograde IFT of the primary cilium we expected the 
DYNC2LI1 protein to be localized to the primary cilium (Fig. 1c)35. Using immunofluorescence analysis 
in ciliated fibroblast cells we confirmed the localization of the DYNC2LI1 protein to the cytoplasm, 
centrosomes, as well as around the basal body, and the transition zone of the primary cilium (Fig.  2). 
To determine the patient’s phenotype on a cellular level we performed immunofluorescence staining on 
human fibroblasts. As patient-derived fibroblasts were not available, the cellular effects of DYNC2LI1 
depletion were examined following siRNA knockdown of DYNC2LI1 and compared to scrambled siRNA. 
The remaining expression rate of DYNC2LI1 was on average 39%. Cilia were examined after siRNA 
transfection and following 5 days of serum starvation to induce ciliogenesis. While cilia were detected 
in the majority of the cells, no significant difference in percentage of ciliated cells was detected (Fig. 3 
a,b: 85% ciliated cells in scrambled controls vs. 84% in DYNC2LI1 depleted cells, p = 0.927 χ 2-test). As 
DYNC2LI1 is part of the dynein-2 complex and defects of other components of this complex have been 
associated with alterations of cilia length and morphology we performed further immunofluorescence 
analysis of the DYNC2LI1 depleted cells. Control cilia showed a mean cilia length of median 1.83 μ m, 
in comparison to cilia in DYNC2LI1 depleted cells, which were only 1.42 μ m long (Fig. 3 c,d). Measured 
differences were highly significant with a p-value of 1.205 × 10−6 [Mann-Whitney-U test]. In addition, 
we observed significantly altered cilia morphology with broadened ciliary tips in 14% of cilia of the 
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DYNC2LI1 depleted cells, compared to 6% abnormal ciliary structures in scrambled controls [p = 0.028 
χ 2-test ] (Fig. 4 a). To study the defect in retrograde IFT due to the abnormal ciliary morphology, we 
stained components of the IFT-B complex IFT57 and IFT88. We observed a localization of these at the 
basal body region of the primary cilium in scrambled controls and knockdown cells. Morphological 
abnormal cilia in DYNC2LI1 depleted cells showed an accumulation of IFT57 and IFT88 in the bulbous 
ciliary tip confirming a retrograde IFT defect in these cells (Fig. 4 b,c).
Discussion
The primary cilium has a pivotal role in a variety of complex processes during pre- and postnatal devel-
opment of almost all vertebrate cells1,14,15. The assembly, maintenance and disassembly of the primary 
cilium is highly controlled throughout the cell cycle to ensure proper function of the associated path-
ways43. Several disorders have been associated with defects of the primary cilium15,24,31. The observed 
phenotypes of these ciliopathies represent alteration of the ciliary pathways and can affect nearly every 
major organ44. Thus, these clinical entities have many clinical features in common. This holds true in 
particular for the group of the skeletal ciliopathies. Here, the most common group constitutes of the 
short-rib thoracic dysplasias (SRTDs), including the asphyxiating thorax dysplasia / Jeune and Ellis-van 
Crefeld syndrome25,32. Jeune syndrome / ATD is distinguished by severely constricted thorax leading to 
Figure 1. Identified mutations in DYNC2LI1 and protein model. (a) Compound heterozygous missense 
and nonsense mutation are located in the nucleoside triphosphate hydrolase domain of DYNC2LI1. (b) 
Model of the nucleoside triphosphate hydrolase domain of DYNC2LI1 in the wild-type and p.Thr221Ile 
mutant. The protein backbone is depicted as cyan tube and residue 221 is shown in space-filled presentation 
and colored according to the atom types. A bound nucleoside diphosphate (GDP) is shown as sticks. 
Alternatively, ADP may be bound at this site, which cannot be safely discriminated at the present 
resolution of the model. (c) Scheme of the primary cilium and known mutations in skeletal ciliopathies 
associated genes (EVC/EVC2 = Ellis-van Crefeld syndrome and WAD; NEK1 = SRTD6; TTC21B = SRTD4; 
IFT80 = SRTD2; IFT43 = CED3; IFT122 = CED1; IFT140 = SRTD9; IFT172 = SRTD10; WDR19 = SRTD5 
and CED4; WDR35 = SRTD7 and CED2; WDR34 = SRTD11; WDR60 = SRTD8; DYNC2H1 = SRTD3; 
DYNC2LI1 = novel intermediate phenotype of our patients)25–30,34. Abbreviations: WAD (Weyers acrofacial 
dysostosis), CED (cranioectodermal dysplasia), SRTD (short-rib thoracic dysplasia).
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respiratory insufficiency, shortened tubular bones and inconsistent polydactyly45–47. Features observed in 
Elli-van Crefeld syndrome are congenital cardiac defects, dysplastic nails and teeth, and labio-gingival 
adhesions, as well as skeletal features like polydactyly, short ribs and limbs48. These entities show signifi-
cant clinical overlap and variable phenotypical expression. The affected individuals of the family reported 
here present with clinical features that include hypoplastic thorax, short stature, polydactyly, hypoplastic 
nails, and atrioventricular septal defects. In accordance with the taxonomy, our patients have been clas-
sified as Jeune-like or EVC.
NGS has been proven to be effective to identify the underlying genetic cause of inherited diseases36–41. 
Concerning the genetic heterogeneity of the skeletal ciliopathies we aimed at the identification of the 
underlying cause in our family by using whole exome sequencing after SureSelect enrichment. After 
Figure 2. Localization of the DYNC2LI1 protein in control fibroblasts. Immunofluorescence staining of 
5 days starved control fibroblasts with antibodies against polyglutamylated tubulin (ciliary axoneme, red), 
DYNC2LI1 (green) and DAPI (DNA, blue in merge) identified localization of DYNC2LI1 to the basal body 
region (a) and to the transition zone (b) of the primary cilium, as well as to the centrosomes (c) during 
mitosis. Magnifications are shown in white boxes, white scale bars 10 μ m.
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excluding mutations in the known genes associated with skeletal ciliopathies we focused on rare, cod-
ing variants in cilia associated genes5,49–52. This identified the two heterozygous mutations c.622C > T 
(p.Arg208Ter) in exon 8 and c.662C > T (p.Thr221Ile) in exon 9 of the DYNC2LI1 gene (Fig.  1 a). In 
agreement with autosomal-recessive inheritance the non-affected family members were heterozygous 
carriers for the identified mutations. These mutations were confirmed by Sanger sequencing and could be 
excluded in further control samples. Both mutations were not present in the 61,486 exomes of the Exome 
Aggregation Consortium and are therefore conserved, rare variants. Mice homozygous for a knockout 
of the orthologous gene Dync2li1tm1Aar are not viable and die before embryonic day 11.553. These mice 
lack monocilia and develop neural tube and cardiac defects, and defects in trunck and tail development. 
Thus, we considered these mutations as most likely disease causing.
Figure 3. Number of primary cilia and cilia length in DYNC2LI1 depleted cells compared to scrambled 
control. Immunofluorescence staining of 5 days starved fibroblasts (scrambled control vs. DYNC2LI1siRNA) 
with antibodies against polyglutamylated tubulin (primary cilium, red), PCNT (green) and DAPI (DNA, 
blue in merge). (a,b) No significant differences in the number of cilium presenting cells were observed, 85% 
of control cells and 84% of DYNC2LI1 depleted cells showed primary cilium formation (p = 0.927 [χ 2-test], 
white scale bars 20 μ m). (c,d) The median cilia length was 1.83 μ m in scrambled control cells, whereas cilia 
in knockdown cells were significantly shorter with median of 1.42 μ m (p = 1.205 × 10−6 [Mann-Whitney-U 
test]). Magnifications are shown in white boxes, white scale bars 10 μ m).
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Figure 4. DYNC2LI1 defect cells present with abnormal cilia morphology confirmed retrograde IFT 
defects. Immunofluorescence staining of 5 days starved fibroblasts (scrambled control vs. DYNC2LI1siRNA) 
with antibodies against polyglutamylated tubulin (primary cilium, red), PCNT/IFT57/IFT88 (green) and 
DAPI (DNA, blue in merge). (a) DYNC2LI1 depleted cells showed in addition to the reduced ciliary length 
further ciliary morphological abnormalities with bulbous tips in 14% of analyzed cilia. Scrambled control 
cells present normal cilia structure, but we observed as well malformations in 6% of measured control cilia 
(p = 0.028 [χ 2-test]). (b) Scrambled controls and knockdown cells showed a localization of IFT57 at the 
basal body region of the primary cilium. In addition, knockdown of DYNC2LI1 resulted in an accumulation 
of IFT57 - component of IFT-B complex - in the bulbous ciliary tip (arrows). (c) IFT88 - another 
component of the IFT-B complex - is localized at the basal body region of the primary cilium in scrambled 
controls and knockdown cells. IFT88 is present at the ciliary tip in scrambled controls compared to a strong 
accumulation in the bulbous tip of DYNC2LI1 depleted cells (arrows). White scale bars 2.5 μ m, three-
dimensional reconstruction was performed using Imaris software (Bitplane, Zurich).
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DYNC2LI1 (D2LIC, LIC3) consists of 3 isoforms (NM_001193464; NM_016008; NM_015522) with 
the longest to be composed of 13 exons encoding a 352-amino-acid-long protein. It is ubiquitously 
expressed with high expression levels in brain, kidney, lung and testes shown in immunoblots of adult 
mice54. In human tissues we confirmed the highest mRNA expression levels in chondrocytes, brain and 
kidney (Supplementary Fig. 3). Significant difference with higher expression levels in fetal tissues was 
observed in brain, lung and kidney. The two longest isoforms are predominantly expressed in all exam-
ined tissues. As our mutations are located in these 2 longest isoforms only, we considered these to have 
a pathogenic effect on skeletal development in our patients and therefore to be disease causing.
DYNC2LI1 has been identified as part of the dynein-2 complex involved in the retrograde transport 
(retrograde IFT)34,35. Loss of cytoplasmic dynein-2 in dync2-li1 zebrafish morphants leads to shorter and 
lower amount of cilia with accumulation of IFT88 near the distal end of the connecting cilium55. These 
morphants have a characteristic phenotype with shortening of the body length, small eyes and kidney 
cysts in 62% as observed in ciliopathies. Interestingly, defects of other components of the dynein-2 com-
plex, DYNC2H1, WDR34, WDR60 in human have been associated with the clinical phenotype of SRPS 
type III, Jeune syndrome / asphyxiating thoracic dystrophy (SRTD3/8/11)34.
Previous studies localized DYNC2LI1 in mammalian cells at the Golgi apparatus and the centroso-
mal region54,56,57. In addition, a localization to the axoneme of ciliated epithelia cells was reported. Our 
immunocytochemistry using an antibody against DYNC2LI1 supported the localization to the centro-
some (Fig. 2c). Moreover, we refined the reported localization in the axoneme to be concentrated at its 
base and at the region of the transition zone (Fig.  2a,b). Even though Madhivanan et al.58 speculated 
that defects of proteins involved in the control of vesicle trafficking to the cilium leads to a more severe 
phenotype than defects of the IFT only, the pronounced clinical phenotypes of patients with dynein-2 
complex defects, Jeune and our patient, do not support this observation.
On the basis of the observed ciliary defects caused by dysfunction of IFT and basal body proteins, we 
expected loss of function of DYNC2LI1 to cause morphological abnormal and missing cilia in humans. 
As we were not able to obtain patient cells, we used immunofluorescence in DYNC2LI1 depleted human 
fibroblasts. We did not observe a significant difference in the percentage of ciliated cells (Fig.  3a,b), a 
significant average size reduction could be detected (Fig. 3c,d). The observation of shorter cilia confirmed 
the results in zebrafish morphants and Dync2li1tm1Aar knockout mice53,55. Reduced cilia length with bul-
bous tip was although reported for defects of DYNC2H1 and WDR34, other components of the dynein-2 
complex28,59. However, one report showed no significant difference in proportion of ciliated cells and 
cilia length in Wdr34-knockdown ATDC5 lines29. In a further component of the dynein-2 complex, 
WDR60, a reduced amount of ciliated cells but normal cilia length was observed in cell lines of affected 
patients30. Together, these data indicate that the reduction of ciliated cells as well as of cilia length is a 
common hallmark of dynein-2 defects. In addition, we showed a higher incidence of cilia with a bulbous 
tip suggesting a defect in microtubule architecture (Fig.  4 a). This was also observed in Dync2li1tm1Aar 
knockout mice where stumpy nodal cilia contain disorganized microtubules, IFT proteins and cellular 
debris53,60. IFT-B proteins to be accumulated in cilia with retrograde IFT transport defects include IFT57 
and IFT8830,61. Morphological abnormal cilia in our knockdown cells showed a significant accumulation 
at the ciliary tip confirming the IFT transport defect in DYNC2LI1 deficient cells (Fig. 4 b,c).
As primary cilia act as sensors for different pathways, the defect of the dynein-2 complex leading to 
retrograde IFT impairment is consistent with impairment of these signaling cascades. Among others, 
defects of the Sonic Hedgehog pathway have been associated with limb-development defects confirming 
the skeletal phenotype in our patients24,62,63.
In conclusion, mutations in members of the dynein-2 complex result in Jeune syndrome / ATD and 
other forms of the SRTD spectrum. Different defects of this complex suggest a correlation between the 
amount of ciliated cells, the resulting cilia length and the functional IFT components with the pheno-
typically overlapping, but variable clinical features. Thus, the identification of mutations in DYNC2LI1 
in our patients expands the phenotypic spectrum of skeletal ciliopathies.
Methods
Subjects and clinical data. Informed consent was obtained from the patients for experimental pro-
tocols and displaying participants’ facial appearances in publications. Peripheral blood samples were 
obtained from the patients as well as control individuals. Genomic DNA from all collected samples was 
extracted according to standard procedures. This study was approved by the Ethical Review Board of the 
Friedrich-Alexander-Universität Erlangen-Nürnberg.
Whole Exome Sequencing. DNA of patient 2 was enriched using the Agilent’s SureSelect Human 
All Exon Kit V3 (Agilent technologies, Santa Clara, CA) and sequenced in single-end reads on a 
SOLiD system (Life Sciences, Santa Clara, CA). Sequenced reads were mapped with LifeScope (Life 
Technologies, Carlsbad, CA) to the reference human genome assembly hg19 (GRCh37). Genotypes were 
additionally called with GATK 2 and SAMtools64–66. For variant annotation ANNOVAR67 (http://www.
openbioinformatics.org/annovar) was used to check on gene information, substitutions of amino acids, 
predictions of SIFT v. 1.03 (http://sift.jcvi.org/)68, PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/)69 
and MutationTaster (http://www.mutationtaster.org/)70, entries of dbSNP132, as well as allele frequen-
cies of the 1000 Genomes Project (http://www.1000genomes.org)71 and NHLBI-ESP 5400. An in-house 
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database consisting of 666 sequenced exomes was also used to exclude sequence errors and frequent 
variants. Graphical presentation of the mapped sequences was viewed with the Integrative Genomics 
Viewer (IGV)72,73. Variants were selected based on autosomal recessive inheritance, their population fre-
quency, the location within the coding sequence (exon, splice site) and the functional effect. The resulting 
variants were Sanger sequenced and the segregation in the family tested
Protein modelling. The domain architecture of DYNC2LI1 was investigated using the InterPro74 and 
Genesilico75 Meta prediction servers. Molecular modelling of residues 28-241 of DYNC2LI1 was per-
formed with Modeller 9.976 using the crystal structure of human RAB5B in complex with GDP (PDB 
code: 2HEI) as a template. The mutation was modeled using SwissModel77 and RasMol was used for 
structure analysis and visualization78.
DYNC2LI1 expression analysis in human tissues. Relative DYNC2LI1 expression was measured by 
quantitative real-time PCR using predesigned TaqMan Gene Expression Assays with the TaqMan Gene 
Expression Mastermix (Life Technologies) specific for all 3 isoforms (Hs00602913_m1, spanning exon 
5-6), isoform 4 (Hs01005273_m1, spanning exon 6-7 of NM_001193464) and isoform 1 (Hs01011588_
m1, spanning exon of 6-7 NM_016008). An isoform 2 (NM_015522) specific probe was designed using 
the Custom TaqMan Assay Design Tool (Life Technologies) for the target region chr2:44021785-44022314 
(3’ UTR).
Expression levels were quantified in quadruplicates for each gene using the Δ Δ Ct method with four 
endogenous control genes (Beta-Actin [huACTB], Beta-2-Microglobulin [huB2M], acidic ribosomal pro-
tein [huPO], phosphoglycerate kinase 1 [huPGK1]).
We used commercially available cDNA panels (Human Fetal MTCTM Panel”, “Human MTCTM Panel 
I” [Clonetech, Mountain View, USA]) covering fetal (whole brain, heart, liver, lung, kidney) and adult 
(whole brain, heart, liver, lung, kidney) tissues to determine the expression pattern of DYNC2LI1 in dif-
ferent human tissues. RNA of osteoblasts and chondrocytes were obtained from 2 different (osteoblasts) 
and 8 different (chondrocytes) adult individuals.
Cell culture. Primary fibroblasts of a healthy control were cultured using Dulbecco’s modi-
fied Eagle medium (DMEM, Life Technologies), patients fibroblasts were not available. Supplements 
were 0–10% fetal calf serum (FCS, Gibco) depending on the experiment and 1% antibiotic mixture 
(Penicillin-Streptomycin-Glutamine; Life Technologies). Transfection of DYNC2LI1 siRNA (HSS147516; 
Life Technologies) was carried out in medium without antibiotics using Lipofectamin 2000 (Life 
Technologies) according to the manufacturer’s instructions. Ciliogenesis was induced by incubating cells 
in serum-free medium (0% FCS) for a period of 5 days.
DYNC2LI1 knockdown. Stealth RNAi™ siRNA Negative Control and 3 DYNC2LI1 Stealth RNAi™ 
siRNAs (HSS182153, HSS147514, HSS147516) were purchased from Life Technologies. The DYNC2LI1 
siRNA HSS147516 with the lowest level of residual activity in control experiments and the corresponding 
Stealth RNAi™ siRNA Negative Control Lo GC (scrambled control 12935-200) were used.
Immunofluorescence. For immunofluorescence analyses cells were fixed with an EGTA-saturated 
ice-cold 100% methanol solution. Cells were treated with 0.01% Tween for 10 min followed by block-
ing of non-specific protein interactions for 60 min with blocking solution (0.5% cold-water fish gelatin 
and 0.1% BSA in PBS). Incubation with primary antibodies (diluted in blocking solution) was per-
formed overnight at 4° C. Centrosomes or the basal body of the primary cilium were stained with 
MmPeriC1 (rabbit, anti-Pcnt pAb, 1:500,79) and the primary cilium was stained with GT335 (mouse, 
anti-Polyglutamylation Modification mAb, 1:1000, AdipoGen, San Diego CA, USA). For DYNC2LI1 
localization studies we used anti-DYNC2LI1 (rabbit, 15949-1-AP, 1:100, Acris, Herford, Germany). 
IFT57 (rabbit, 11083-1-AP, 1:100, Proteintech, Manchester, United Kingdom) and IFT88 (rabbit, 13967-
1-AP, 1:200, Proteintech, Manchester, United Kingdom) antibodies were used for accumulations studies 
of IFT-B proteins in ciliary tips. Alexa Fluor® 488 goat anti- rabbit IgG (green, 1:500) and Alexa Fluor® 
594 goat anti-mouse IgG (red, 1:500) (Life Technologies) were used as secondary antibodies and cell 
nuclei were stained with DAPI (4′ ,6-Diamidin-2-phenylindol, 1:50000, Serva, Heidelberg, Germany). 
Samples were mounted in Aqua Poly Mount (Polysciences, Eppelheim, Germany) and analyzed with a 
Zeiss Axio Imager Z2 fluorescence microscope equipped with an Apotome. Projections of z-stacks were 
calculated with AxioVision 4.8 software (Zeiss, Oberkochen, Germany) and the images were adjusted for 
brightness and contrast using Adobe Photoshop CS (Adobe, San Jose, CA). The length of primary cilia 
was measured with the FIJI program80.
We performed three-dimensional reconstruction of cilia using Imaris software 7.7 (Bitplane, Zurich, 
Switzerland) with picture stacks from a Laser Scanning Microscope 710 (Carl Zeiss) and ZEN 2010 
software with corresponding imaging modules.
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